Stock News

Raymond James Financial Services Advisors Has Upped Affiliated Managers Group (AMG) Position By $908,150; Quest Diagnostics (DGX)’s Sentiment Is 0.92

Affiliated Managers Group, Inc. (NYSE:AMG) Logo

Quest Diagnostics Inc (DGX) investors sentiment decreased to 0.92 in Q4 2017. It’s down -0.06, from 0.98 in 2017Q3. The ratio dived, as 225 investment professionals opened new or increased positions, while 244 reduced and sold their stock positions in Quest Diagnostics Inc. The investment professionals in our database now own: 115.48 million shares, down from 116.90 million shares in 2017Q3. Also, the number of investment professionals holding Quest Diagnostics Inc in top ten positions was flat from 2 to 2 for the same number . Sold All: 52 Reduced: 192 Increased: 158 New Position: 67.

Raymond James Financial Services Advisors Inc increased Affiliated Managers Group (AMG) stake by 173.93% reported in 2017Q4 SEC filing. Raymond James Financial Services Advisors Inc acquired 4,430 shares as Affiliated Managers Group (AMG)’s stock declined 9.29%. The Raymond James Financial Services Advisors Inc holds 6,977 shares with $1.43M value, up from 2,547 last quarter. Affiliated Managers Group now has $9.16B valuation. The stock increased 1.20% or $2 during the last trading session, reaching $168.56. About 121,801 shares traded. Affiliated Managers Group, Inc. (NYSE:AMG) has risen 16.50% since May 16, 2017 and is uptrending. It has outperformed by 4.95% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 13 selling transactions for $30.90 million activity.

More news for Quest Diagnostics Incorporated (NYSE:DGX) were recently published by: Seekingalpha.com, which released: “Premarket analyst action – healthcare” on May 01, 2018. Globenewswire.com‘s article titled: “Report: Exploring Fundamental Drivers Behind Valvoline, KKR & Co., Otonomy, Radian Group, Red Rock Resorts, and …” and published on May 11, 2018 is yet another important article.

Analysts await Quest Diagnostics Incorporated (NYSE:DGX) to report earnings on July, 24. They expect $1.72 earnings per share, up 10.97% or $0.17 from last year’s $1.55 per share. DGX’s profit will be $233.60 million for 14.86 P/E if the $1.72 EPS becomes a reality. After $1.52 actual earnings per share reported by Quest Diagnostics Incorporated for the previous quarter, Wall Street now forecasts 13.16% EPS growth.

The stock increased 0.12% or $0.12 during the last trading session, reaching $102.25. About 355,796 shares traded. Quest Diagnostics Incorporated (DGX) has risen 1.33% since May 16, 2017 and is uptrending. It has underperformed by 10.22% the S&P500.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $13.89 billion. The companyÂ’s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It currently has negative earnings. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.

Ratings analysis reveals 67% of Quest Diagnostics’s analysts are positive. Out of 6 Wall Street analysts rating Quest Diagnostics, 4 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $86.0 while the high is $110.0. The stock’s average target of $98.50 is -3.67% below today’s ($102.25) share price. DGX was included in 6 notes of analysts from August 31, 2016. The stock of Quest Diagnostics Incorporated (NYSE:DGX) earned “Buy” rating by UBS on Monday, November 14. Deutsche Bank initiated Quest Diagnostics Incorporated (NYSE:DGX) rating on Wednesday, January 18. Deutsche Bank has “Buy” rating and $108.0 target. On Wednesday, April 12 the stock rating was maintained by FBR Capital with “Outperform”. On Friday, September 9 the stock rating was initiated by Citigroup with “Neutral”. The rating was downgraded by Mizuho on Wednesday, August 31 to “Neutral”. The company was upgraded on Monday, December 12 by Goldman Sachs.

Healthinvest Partners Ab holds 5.92% of its portfolio in Quest Diagnostics Incorporated for 28,500 shares. Polaris Capital Management Llc owns 2.55 million shares or 2.74% of their US portfolio. Moreover, Financial Advantage Inc. has 2.38% invested in the company for 30,496 shares. The Rhode Island-based Weybosset Research & Management Llc has invested 2.25% in the stock. Rockefeller Financial Services Inc, a New York-based fund reported 1.25 million shares.

Another recent and important Affiliated Managers Group, Inc. (NYSE:AMG) news was published by Globenewswire.com which published an article titled: “AMG to Announce First Quarter Results on April 30, 2018” on April 24, 2018.

Since March 7, 2018, it had 0 insider purchases, and 1 insider sale for $5.69 million activity. Another trade for 30,000 shares valued at $5.69 million was sold by Horgen Jay C..

Raymond James Financial Services Advisors Inc decreased Brown Forman Corp (NYSE:BF.B) stake by 4,833 shares to 6,818 valued at $468,000 in 2017Q4. It also reduced Adams Diversified Equity Fd (ADX) stake by 67,496 shares and now owns 181,646 shares. Roper Technologies Inc (NYSE:ROP) was reduced too.

Among 10 analysts covering Affiliated Managers Group (NYSE:AMG), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. Affiliated Managers Group had 57 analyst reports since August 9, 2015 according to SRatingsIntel. The stock of Affiliated Managers Group, Inc. (NYSE:AMG) has “Buy” rating given on Tuesday, January 26 by Deutsche Bank. The firm has “Buy” rating by Wood given on Wednesday, April 5. Credit Suisse downgraded the stock to “Neutral” rating in Wednesday, January 3 report. On Wednesday, January 10 the stock rating was maintained by Jefferies with “Buy”. The stock has “Buy” rating by Citigroup on Tuesday, January 30. On Monday, September 25 the stock rating was maintained by Jefferies with “Buy”. Citigroup upgraded it to “Buy” rating and $215 target in Monday, April 25 report. Citigroup downgraded Affiliated Managers Group, Inc. (NYSE:AMG) rating on Monday, June 5. Citigroup has “Hold” rating and $18000 target. Goldman Sachs maintained Affiliated Managers Group, Inc. (NYSE:AMG) rating on Monday, March 21. Goldman Sachs has “Buy” rating and $190 target. The firm has “Outperform” rating given on Friday, August 11 by Credit Suisse.

Affiliated Managers Group, Inc. (NYSE:AMG) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *